Table 1. The patients’ baseline characteristics before antiviral therapy (n = 196).
| Baseline | SVR24 | P-value | |
|---|---|---|---|
| Age (years)† | 62 (29–89) | ||
| Sex (female/male) | 107/89 | ||
| BMI (kg/m2)† | 23 (14.8–35.5) | ||
| Diabetes mellitus (yes/no) | 22/174 | ||
| Genotype (1/2) | 136/60 | ||
| HCV RNA (log10 IU/mL)† | 6.2 (2.4–7.4) | ||
| ALT (IU/L)† | 39 (8–528) | 16 (6–166) | <0.001 |
| AST (IU/L)† | 38 (12–269) | 23 (10–136) | <0.001 |
| GGTP (IU/L)† | 36 (9–1,470) | 21 (8–781) | <0.001 |
| Albumin (g/dL)† | 4.2 (2.1–4.9) | 4.4 (2.6–5.2) | <0.001 |
| Total bilirubin (mg/dL)† | 0.63 (0.27–4.55) | 0.68 (0.26–3.46) | 0.127 |
| Platelet count (×103/μL)† | 16.1 (5.3–49.1) | 16.8 (5.7–46) | 0.044 |
| AFP (ng/mL)† | 4.1 (8–123.7) | 3.1 (0.6–16.9) | <0.001 |
| DCP (mAU/mL)† | 19 (10–207) | 20 (10–72) | 0.38 |
| Fibrosis 4 index† | 2.56 (0.39–12.13) | 2.04 (0.42–10.88) | <0.001 |
| SWE (kPa)† | 8.3 (3.4–36.2) | 5.9 (2.7–31.3) | <0.001 |
| Follow-up duration (months)† | 26 (5–109) | ||
| Therapy (IFN-based/DAAs) | 89/107 |
†Values are expressed as median (range).
AFP, alpha fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DCP, des-gamma carboxyprothrombin; GGTP, gamma-glutamyl transpeptidase; HCV, hepatitis C virus; IFN, interferon; DAAs, direct-anting agents; SVR24, sustained virological response at week 24; SWE, shear wave elastography.